JBL and CLS are positioned to benefit from AI, cloud and data center demand, but both face competitive, trade and segment challenges.
Sanmina Corporation (SANM) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q2
while the company demonstrates strong cash conversion with an 8.5% FCF margin, the 53.04 P/E TTM and the recent surge in debt to $2.2 billion warrant further investigation into the sustainability of current growth cycles.
Sanmina Corporation (SANM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Sanmina Corporation (SANM) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 27, 2026 | $3.16vs $2.42+30.6% | $4.0Bvs $3.3B+22.2% |
| Q1 2026 | Jan 26, 2026 | $2.38vs $2.15+10.7% | $3.2Bvs $3.1B+3.7% |
| Q4 2025 | Nov 3, 2025 | $1.67vs $1.57+6.4% | $2.1Bvs $2.1B+1.9% |
| Q3 2025 | Jul 28, 2025 | $1.53vs $1.42+7.7% | $2.0Bvs $2.1B-0.5% |
Recent stock market news and headlines for Sanmina Corporation (SANM)
JBL and CLS are positioned to benefit from AI, cloud and data center demand, but both face competitive, trade and segment challenges.
Compare sector allocations, risk profiles, and long-term growth potential as these two funds target distinct corners of the US equity market.

HINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into a Letter of Agreement (LOA) with Sanmina Corporation, a leading global integrated manufacturing solutions provider, to manufacture the LIBERTY System, the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures.

Sanmina is rated buy with a $312 price target, driven by strong ZT Systems integration and accelerating AI infrastructure demand. Q2 FY26 revenue surged 102% YoY to $4.01B, with ZT Systems contributing $1.88B and future growth underpinned by next-gen product ramps. SANM's strategic focus on vertical integration, customer diversification, and U.S. manufacturing positions it for margin expansion and de-risked FY27 revenue.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Key metrics vs top competitors for Sanmina Corporation (SANM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $205.75 | $11.23B | 46.13 | 7.4% | 3.03% | 10.04% | — | |
| $321.08 | $33.87B | 54.24 | 3.18% | 2.57% | 62.24% | — | |
| $345.06 | $39.67B | 47.33 | 30.71% | 6.95% | 47.71% | — | |
| $131.52 | $48.19B | 56.45 | 8.14% | 3.15% | 17.26% | — | |
| $81.01 | $2.91B | 119.13 | 0.11% | 1.27% | 3.1% | — | |
| $255.94 | $6.86B | 40.89 | 1.82% | 4.35% | 12.83% | — |
Sanmina Corporation (SANM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Sanmina Corporation (SANM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 27, 2026·SEC
Mar 12, 2026·SEC
Jan 26, 2026·SEC
Get notified when SANM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Sanmina Corporation (SANM) stock FAQ — growth, dividends, profitability & financials explained
Sanmina Corporation (SANM) reported $11.34B in revenue for fiscal year 2025. This represents a 4178% increase from $265.1M in 1996.
Sanmina Corporation (SANM) grew revenue by 7.4% over the past year. This is steady growth.
Yes, Sanmina Corporation (SANM) is profitable, generating $259.6M in net income for fiscal year 2025 (3.0% net margin).
Sanmina Corporation (SANM) has a return on equity (ROE) of 10.0%. This is reasonable for most industries.
Sanmina Corporation (SANM) generated $734.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.